We are fond of developing advanced drug delivery solutions, including targeted precision systems. In this patent, you can find a great approach to such a process by combining cyclodextrin with Galnac for liver targeting.
Liver-targeted drug delivery carrier as well as preparation method and application
In the past few years, we have created dozens of educational materials on various uses of cyclodextrin, such as complex preparation, monoclonal antibody formulation, uses in vaccines, gene therapy, and various non-pharma applications.
We collected these decks for you in two easy-to-digest platforms.
Here you can find (and download) the decks: https://www.carbohydesolutions.com/natures-gift-for-mankind-are-cyclodextrins/
On our YouTube channel, you can watch them as short videos:
https://www.youtube.com/@CarboHyde
Learn and enjoy!
today’s cyclodextrin:
I brought some applications from the textile industry. Interestingly, there are no real successful commercial examples (that I know of, at least) using CDs in the textile industry. Yet there are so many inventions in the field, I am sure, this is just a matter of time. These two applications are both interesting, on is and ultraviolet-resistant application, the other is a flame-retardant material.
Flame-retardant non-woven fabric and preparation process
Anti-ultraviolet multifunctional textile fiber material and preparation method thereof
Check out this fascinatnig discussion on next future of cyclodextrin-based antidotes and scavengers by J Robert Sneyd adn Jennifer Hunter.
Spoiler alert: Phase 3 clinical trials suggest that Adamgammadex is slightly less potent than sugammadex and has a non-inferior speed of onset. In a multicentre trial of 310 patients, there was a suggestion of a lower incidence of allergic responses and recurarisation after adamgammadex compared with sugammadex.
If you are also thinking about creating a special cyclodextrin like that, this may be useful for you: Custom synthesis of cyclodextrins – www.carbohydesolutions.com
Today’s cyclodextrin:
One of the greatest features of CDs is that with a proper application (especially when the local CD concentration is relatively high), they can not only improve the solubility but also the permeability of compounds. For example, in the case of a peroral application, let’s say an orally disintegrating tablet. Not to mention that their taste masking potential is also of use in this case. 3 birds with one stone!
In this paper, you can find a great example of such a smart application. If you are interested in developing similar formulations, check out the first steps here: Formulation development – www.carbohydesolutions.com
For more than a decade, the CRISPR toolbox and its applications have profoundly changed biological research, enabling advances through applications in plants, animals, and humans.
As we reported earlier CarboHyde is part of an EU-sponsored 4-year long staff-exhange project, Bicyclos.
Bicyclos is a staff exchange project funded by the Horizon Europe Framework Programme after successful application in the call HORIZON-MSCA-2022-SE-01-01. The project started on September 1st, 2023. We are 9 beneficiaries and 2 associated partners coming from 8 countries in Europe and America. We are all interested in fostering progress of cyclodextrins in biomedical applications.
During this project, CarboHyde staff will spend 30+ months abroad and will host students for 40+ months in the upcoming 4 years doing high level science on moonshot projects – of course, all based on cyclodextrins.
Now its time to start our first journey, as our excellent chemist, Kristóf Felegyi is going to Seville for 5 months to make some fancy compounds at the lab of Jose Manuel Garcia Fernandez.
Farewell Kristof, we expect you back soon!
Today’s cyclodextrin is another industrial application, now from the material sciences: a washable ink!
The cyclodextrin is said to be included to improve the washability and vividness of the shades of a washable aqueous ink composition. According to the patent, in this particular application HPBCD is used, yet I think that would be more composition dependent.
Link to patent: https://worldwide.espacenet.com/publicationDetails/claims?CC=US&NR=2023383132A1&KC=A1&FT=D&ND=&date=20231130&DB=EPODOC&locale=en_EP
We have known for a while that methylated β-cyclodextrin (MβCD) can extract cholesterol from lipid rafts and induce apoptosis in cancer cells by inhibiting activation of the PI3K-Akt-Bad pathway.
In this study from Kumamoto University (Keiichi Motoyama), MβCD with mannose (Man-MβCD) is assessed for targeting colon cancer cells expressing the mannose receptor (MR) and tumor-associated macrophages (TAM). Man-MβCD showed a significantly greater level of cellular association with colon-26 cells and M2 macrophages, and much more prominent anticancer activity than that of MβCD against MR-positive colon-26 cells. These results revealed that autophagy was the main mechanism of cell death associated with Man-MβCD. Furthermore, compared with MβCD, Man-MβCD significantly reduced tumor development following intravenous delivery to tumor-bearing mice, with no apparent side effects. Thus, Man-MβCD has the potential to be a novel anticancer drug.
If you would like to try something like this, check out this site for ideas: Custom synthesis of cyclodextrins – www.carbohydesolutions.com
Today’s cyclodextrin
Reading this paper from Yeungnam University by Jong Oh Kim et al reminded me about a core application of CD’s: improving oral bioavailability of compounds. While this feature does not work generally on all compounds, it certainly does on the ones, where the poor solubility is the main cause of the low oral bioavailability. On the other hand, this feature of CD’s often make developing generic drugs with this excipients impossible, while creating improved/added value reformulations of repurposed APIs remains a target use.
If you have projects like this on your table, you might find it useful to check this website: Development of abiraterone acetate tablets with enhanced oral bioavailability | Journal of Pharmaceutical Investigation (springer.com)